TAVR for Women: What the Research Shows About Sex Differences in Outcomes

If you have been told you need a TAVR, or you are helping someone who has, you probably have a lot of questions. This article covers what the procedure is, what the research shows about women, why the differences may exist, and what to ask the heart team before you agree to anything.

What is aortic stenosis?

The aortic valve controls blood flow from the heart into the body. Aortic stenosis is a narrowing of that valve. It develops over time, and it makes the heart work harder to push blood through. A 2026 systematic review describes it as a life-threatening condition, because severe narrowing can lead to heart failure.

Symptoms often develop slowly. People may notice less energy, shortness of breath with activity, chest pressure, or fainting. Some people have no symptoms for a long time, which is one reason the condition is sometimes found during routine tests.

What is TAVR?

Transcatheter aortic valve replacement, or TAVR, replaces the narrowed valve through a catheter, a thin, flexible tube. The replacement valve is folded up, guided through a blood vessel (usually in the groin), and placed inside the old valve. The 2026 systematic review describes TAVR as the definitive treatment for this condition, and it does not require open-heart surgery for everyone.

Whether TAVR is the right choice depends on your heart, your other health conditions, your age, your goals, and your anatomy. A heart team of cardiologists, surgeons, and other specialists usually makes the decision with you. Surgery and TAVR are both options for some patients, and the team should explain the trade-offs in plain language.

What do the 2026 studies show for women?

A 2026 meta-analysis combined individual patient data from 71 studies, with 481,353 patients. It compared outcomes for women and men after TAVR. Compared with men, women had a higher short-term risk of:

• Death within 30 days. Hazard ratio 1.06 (95% confidence interval 1.005 to 1.127).
• Stroke or transient ischemic attack (TIA). Hazard ratio 1.51 (95% confidence interval 1.317 to 1.734). A TIA is a temporary stroke-like event.
• Major bleeding. Relative risk 1.26 (95% confidence interval 1.13 to 1.41).
• Vascular complications. Problems with the blood vessels used to reach the heart. The authors reported higher early risk for women.

The same analysis found that women had a long-term survival advantage over men after the procedure. The early risks are higher for women, but women tended to live longer afterward.

A 2025 study of stroke after TAVR also reported that women have historically had higher rates of bleeding and vascular complications, and a 2025 study of 379,410 TAVR patients in a national inpatient database (2016 to 2021) found that women had higher in-hospital stroke rates than men (2.31% vs 1.69%). The difference was driven mainly by disabling strokes (1.61% vs 1.01%). A separate 2026 systematic review reached a similar picture, describing women as having higher short-term mortality, vascular complications, and major bleeding, despite generally better long-term survival.

Why might outcomes differ?

The reasons are not fully settled. Several factors may contribute, and they probably work together:

• Blood vessel size. Women often have smaller blood vessels than men. Some researchers think that difference can affect how a catheter moves through the body and how vessels respond to the procedure.
• Other health conditions and age. Women who reach TAVR may differ from men in age and in other conditions, and those differences affect risk.
• Procedure planning and device choice. Newer device designs are being studied for vascular complications, but the evidence is still developing.

What this means for you: the early risks are real, and they should be part of the discussion. They are not a reason to avoid the procedure automatically, and the long-term picture is more favorable for women in these studies. The right question is what the risks mean for your specific case.

What should I ask the heart team?

• What are my specific risks for stroke, bleeding, and blood vessel complications, and how do they compare with the other options?
• How are you planning the procedure for my vessel size and valve size?
• Will a women's heart team or a team experienced with women patients be involved in my care?
• What does recovery look like for me, and what should I watch for at home?
• What follow-up will we have, and how will my heart function be tracked over time?
• Are there trials or registries that include women like me?

Ask for these answers in writing if you can. A written plan is easier to share with family and with your primary clinician.

How should I prepare?

Ask the team what preparation they recommend. This often includes a review of your medicines, tests of your heart and blood vessels, and a plan for who will drive you home and help you in the first days. Bring a list of all your medicines and supplements, and tell the team about any bleeding problems or blood thinners you take.

What should I watch for after the procedure?

Call emergency services right away if you have sudden weakness or numbness on one side of the body, trouble speaking, vision loss, chest pain, severe shortness of breath, fainting, or bleeding that does not stop. Ask your team for a written list of warning signs before you leave the hospital, and keep it where your family can find it.

How does the heart team decide?

Decisions about TAVR are usually made by a heart team, which can include cardiologists, cardiac surgeons, and imaging specialists. The team looks at the valve and heart function, your other health conditions, your age and goals, and the size and shape of your blood vessels and valve. Some patients are better suited to TAVR, and others to surgery, and some are not candidates for either.

Ask the team to explain how they reached their recommendation, and whether a second opinion is available. A recommendation that is explained in plain words is easier to weigh against your own priorities.

What do these studies not tell you?

The studies above are large, and they show useful patterns. They also have limits. Many pool data from studies that were not designed to compare men and women directly. The 2026 systematic review (PMID 42540485) rated its included studies as moderate to high in methodological quality, which is a reasonable starting point. It does not replace a conversation about your own anatomy, health, and goals.

Two practical points follow. First, an average result is not a forecast for one person. Second, the most useful numbers are the ones your heart team calculates for you. Ask for them.

This article is general information, not medical advice. It does not replace the advice of your heart team. Never make decisions about heart procedures based on an article alone.